Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.

• Revenue in AUD (TTM)256.62k
• Net income in AUD-40.50m
• Incorporated1987
• Employees19.00

• Location
  Immutep LtdPlaza Building, L 12 95 Pitt StSYDNEY NSW 2000AustraliaAUS
• Phone+61 28315-7003
• Fax+61 28569-1880
• Websitehttps://www.immutep.com/